FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

						( ) -											
1. Name and Address of Reporting Person*  KELLER WILLIAM R						2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
KELLER WILLIAM R					ALXN]							X Directo	r	10% Ow	/ner		
(4.0)						-						Officer below)	(give title	Other (s below)	pecify		
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year)						bciow)		belowy			
C/O ALEXION PHARMACEUTICALS, INC. 352 KNOTTER DRIVE					05/11/2011												
					4. If Amendment, Date of Original Filed (Month/Day/Year)						6 In	6. Individual or Joint/Group Filing (Check Applicable					
(Ctroot)				—   <del>"</del>	II AIIIC	mament, D	ale o	i Original i lie	a (Month/Da	y/ rear)	Line		omir Group i mili	(Check App	ilicable		
(Street) CHESHI	RE C	г	06410									X Form fi	led by One Rep	orting Persor	1		
CHESTIKE CI 00410										Form filed by More than One Reporting Person							
(City)	(S	tate)	(Zip)														
		Tal	ole I - Non-D	Derivativ	re Se	curities	Ac	quired, Di	sposed o	f, or Ber	eficiall	y Owned					
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					Execution Date			Code (Instr. 5)				4 and Securities Beneficially Owned Following		n: Direct I r Indirect I sstr. 4) (	7. Nature of ndirect Beneficial Ownership		
								Code V	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)	[	Instr. 4)		
			Table II - De									Owned	•				
			(e.	g., puts	, call	s, warra	ants	, options,	convertib	ole secu	rities)						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	Code	Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
											Amount		(Instr. 4)				
									L		Number						
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	of Shares						
Option to Purchase Common Stock	\$98.86	05/11/2011		A		2,786 <sup>(1)</sup>		08/11/2011	05/11/2021	Common Stock, par value \$.0001 per share	2,786	\$0	2,786	D			

## **Explanation of Responses:**

1. These options will vest in four quarterly investments during the one year period commencing on May 11, 2011 and ending on May 11, 2012.

/s/ William Keller

05/13/2011

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.